Recent Price Performance and Market Comparison
Syncom Formulations has been under pressure in the short term, with its stock price falling by 2.27% over the past week, contrasting with the Sensex’s modest gain of 0.20% during the same period. The one-month performance is even more pronounced, with the stock declining 11.69%, while the benchmark index dipped only 0.46%. Year-to-date, the stock has lost 26.75%, a stark contrast to the Sensex’s 8.22% gain. Over the last year, the stock’s return stands at a negative 31.89%, whereas the Sensex has appreciated by 4.80%. These figures highlight a significant underperformance relative to the broader market.
On 17-Dec, the stock traded close to its 52-week low, just 3.75% above the lowest price of ₹14.10, signalling persistent weakness. The stock has also underperformed its sector by 1.32% on the day, and it has declined for two consecutive days, losing 2.46% in that span. Technical indicators further reinforce the bearish sentiment, with the share price trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Financial Strength and Positive Operational Metrics
Despite the recent price weakness, Syncom Formulations has demonstrated robust operational performance in the recent half-year period. The company reported a 25.87% growth in net sales, reaching ₹238.62 crores, alongside an 8.29% increase in operating profit. Profit after tax (PAT) surged by 72.46% to ₹32.32 crores over the latest six months. The company has also maintained positive results for six consecutive quarters, indicating consistent earnings momentum.
Return on capital employed (ROCE) stands at a healthy 22.06%, while return on equity (ROE) is 16.6%, suggesting efficient utilisation of capital. The company’s low average debt-to-equity ratio of 0.05 times further underscores its conservative financial structure. Valuation metrics show a price-to-book value of 3.6, which is a premium compared to peers’ historical averages. Interestingly, the company’s price-to-earnings-to-growth (PEG) ratio is 0.2, indicating that the stock may be undervalued relative to its earnings growth potential.
Long-Term Challenges and Market Sentiment
However, the company’s long-term growth trajectory raises concerns. Over the past five years, net sales have declined at an annualised rate of 63.63%, and operating profit has contracted by 52.27% annually. This poor long-term growth record contrasts sharply with the recent half-year improvements and may be contributing to investor caution.
Market participation also appears subdued. Domestic mutual funds hold no stake in Syncom Formulations, which is notable given their capacity for detailed company research. This absence could reflect a lack of confidence in the company’s prospects or valuation at current levels. Furthermore, the stock’s liquidity, while adequate for small trade sizes, has seen a decline in delivery volume by 5.84% compared to the five-day average, signalling reduced investor interest.
Considering Syncom Formul.? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this Smallcap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Conclusion: Why the Stock is Falling
In summary, Syncom Formulations’ share price decline on 17-Dec and recent underperformance can be attributed to a combination of factors. While the company has posted encouraging recent earnings growth and maintains a strong balance sheet, its long-term sales and profit declines weigh heavily on investor sentiment. The stock’s proximity to its 52-week low, consistent underperformance relative to the Sensex and sector, and weak investor participation further exacerbate the downward pressure.
Investors appear cautious, likely due to the disconnect between recent operational improvements and the company’s historical growth challenges. The absence of domestic mutual fund interest and declining delivery volumes suggest limited confidence in a sustained recovery. Until the company can demonstrate consistent long-term growth and attract broader institutional support, the stock may continue to face selling pressure despite its positive short-term fundamentals.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
